Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics.
– In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast.
– HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms.
– A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and five drugs in Phase II.
– Over the past 10 years, the US has hosted the highest number of trial sites for HCM, at nearly 281 trial sites.
– In North America, mergers and acquisitions were more evenly distributed deal types during the past decade. In Europe, acquisitions and asset transactions were equally divided.
Scope
GlobalData’s Hypertrophic Cardiomyopathy Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include –
– Disease Landscape
– Disease Overview
– Epidemiology Overview
– Treatment Overview
– Marketed Products Assessment
– Breakdown by Mechanism of Action, Route of Administration
– Product Profiles with Sales Forecast
– Pricing and Reimbursement Assessment
– Annual Therapy Cost
– Time to Pricing and Time to Reimbursement
– Pipeline Assessment
– Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Late-to-mid-stage Pipeline Drugs
– Phase Transition Success Rate and Likelihood of Approval
– Clinical Trials Assessment
– Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
– Enrolment Analytics, Site Analytics, Feasibility Analysis
– Deals Landscape
– Mergers, Acquisitions, and Strategic Alliances by Region
– Overview of Recent Deals
– Commercial Assessment
– Key Market Players
– Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Hypertrophic Cardiomyopathy Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hypertrophic Cardiomyopathy Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Hypertrophic Cardiomyopathy reports